Document:

INDEPENDENT DIRECTOR AGREEMENT 

  
 

  
THIS INDEPENDENT DIRECTOR AGREEMENT (this “Agreement”) is made effective as of [*], 20   by and between Neuralstem, Inc.  (the “Company”), and [*] (“Director”). 

  
 

  
WHEREAS, the Company seeks to attract and retain as directors, capable and qualified persons to serve on the Company’s board of directors (the “Board”); and 

  
 

  
WHEREAS, the Company has requested and received from Director certain information regarding Director’s qualifications and fitness to serve on the Board and has considered and relied upon the accuracy of such information in offering Director the opportunity to serve on the Board; and 

  
 

  
WHEREAS, the Company believes that Director possesses the necessary qualifications and abilities to serve as a director of the Company and to perform the functions and meet the Company’s needs related to its Board. 

  
 

  
NOW, THEREFORE, the parties agree as follows: 

  
 

  
1.               Service to the Board and Duties. 

  
 

  
(a)             Duties.  During the Directorship Term (as defined herein), the Director shall serve as a member of the Board, and the Director shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities and have the authority commensurate to such position. 

  
 

  
(b)             Service to the Board.  During the Directorship Term, the Director may continue to serve in other non-Company related positions, and assume duties and responsibilities consistent with, the position of an independent non-executive director, provided, however, that under no circumstances may the Director engage in or undertake any other positions, duties, responsibilities or assignments that materially interfere with his duties to the Company. The Director agrees to devote the necessary working time, skill, energy and best business efforts and exercise his independent business judgment during the term of his service on the Board of the Company. The Director fully understands the (i) duty of loyalty, (ii) duty of confidentiality, (iii) duty to abide by all relevant securities laws of the United States and any other jurisdictions in personal and corporate conduct, (iv) duties of due care and good faith in the performance of his service as a Director and (v) role of a Director in protecting stockholders’ rights.  Notwithstanding anything to the contrary contained herein, the Director may hold officer and non-executive director positions (or the equivalent position) in or at other entities that are not affiliated with the Company. 

  
 

  
(c)             Service on Committees. Director will serve on the following committees and in the capacities stated: 

  
 

  	
  
 

	
  
Member

	
  
 

	
  
Chairperson

	
  
Audit Committee

	
  
—

	
  
 

	
  
—

	
  
Compensation/Nominating Committee

	
  
—

	
  
 

	
  
—

	
  
Corporate Governance Committee

	
  
—

	
  
 

	
  
—

  
 

  
To the extent Director serves as Audit Committee Chairperson, Director agrees that Director is also serving as the financial expert for purposes of filings before the Securities and Exchange Commission.

  
 

  
 

  

  
 

  
2.               Term. The term of this Agreement (“Directorship Term”) shall commence as of the date of Director’s appointment by the Board of Directors of the Company and shall continue until the earliest of the following; (1) the death of the Director, (2) the termination of the Director from his membership on the Board by the mutual agreement of the Company and the Director, (3) the removal of the Director from the Board by the majority stockholders of the Company, or (4) the resignation by the Director from the Board. 

  
 

  
3.                Compensation and Expenses. 

  
 

  
 See attached Schedule A. 

  
 

  
4.                Insurance.  The Company shall, at its discretion, obtain and maintain a policy or policies of director and officer liability insurance (“D&O Insurance”) during the whole period when the Director is on the Board, in an amount not less than $[*], of which the Director will be named as an insured, providing the Director with coverage subject to the provisions of an indemnification agreement (“Indemnification Agreement”) entered into by the Company and Director.

  
 

  
5.               Director’s Representation and Acknowledgment.  The Director represents to the Company that his execution and performance of this Agreement shall not be in violation of any agreement or obligation (whether or not written) that he may have with or to any person or entity, including without limitation, any prior or current employer. The Director hereby acknowledges and agrees that this Agreement (and any other agreement or obligation referred to herein) shall be an obligation solely of the Company, and the Director shall have no recourse whatsoever against any stockholder of the Company or any of their respective affiliates with regard to this Agreement.

  
 

  
6.               Requirements of Director.  During the term of the Director’s services to the Company hereunder, Director shall observe all applicable laws and regulations relating to independent directors of a public company as promulgated from time to time, and shall not: (1) be an employee of the Company or any Parent or Subsidiary; (2) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the Company other than as a director and/or a member of a committee of the Board; (3) be an affiliated person of the Company or any Parent or Subsidiary, as the term “affiliate” is defined in 17 CFR 240.10A-3(e)(1), other than in his capacity as a director and/or a member of a committee of the Board; (4) possess an interest in any transaction with the Company or any Parent or Subsidiary, for which disclosure would be required pursuant to 17 CFR 229.404(a), other than in his capacity as a director and/or a member of a committee of the Board committees; (5) be engaged in a business relationship with the Company or any Parent or Subsidiary, for which disclosure would be required pursuant to 17 CFR 229.404(b), except that the required beneficial interest therein shall be modified to be 5% hereby.

  
 

  
7.               Reporting Obligations.  While this Agreement is in effect, the Director shall immediately report to the Company in the event: (1) the Director knows or has reason to know or should have known that any of the requirements specified in Section 6 hereof is not satisfied or is not going to be satisfied; and (2) the Director simultaneously serves on an audit committee of any other public company.

  
 

  
 

  

  
 

  
8.               Director Covenants. 

  
 

  
(a)             Unauthorized Disclosure.  The Director agrees and understands that in the Director’s position with the Company, the Director has been and will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited to, technical information, business and marketing plans, strategies, customer information, other information concerning the Company’s products, promotions, development, financing, expansion plans, business policies and practices, and other forms of information considered by the Company to be confidential and in the nature of trade secrets. The Director additionally agrees to not disclose any information regarding the Board of the Company whether it be subjects of Board meetings, Board discussions and correspondence, Board opinions, or any other information disseminated by any of the Board of Director in their capacity as directors of the Company.  The Director agrees that during the Directorship Term and thereafter, the Director will keep such information confidential and will not disclose such information, either directly or indirectly, to any third person or entity without the prior written consent of the Company; provided, however, that (i) the Director shall have no such obligation to the extent such information is or becomes publicly known or generally known in the Company’s industry other than as a result of the Director’s breach of his obligations hereunder and (ii) the Director may, after giving prior notice to the Company to the extent practicable under the circumstances, disclose such information to the extent required by applicable laws or governmental regulations or judicial or regulatory process. This confidentiality covenant has no temporal, geographical or territorial restriction. Upon termination of the Directorship Term, the Director will promptly return to the Company and/or destroy at the Company’s direction all property, keys, notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data, other products or documents, and any summary or compilation of the foregoing, in whatever form, including, without limitation, in electronic form, which has been produced by, received by or otherwise submitted to the Director in the course or otherwise as a result of the Director’s position with the Company during or prior to the Directorship Term, provided that, the Company shall retain such materials and make them available to the Director if requested by him in connection with any litigation against the Director under circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that the materials are necessary to his defense in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction of the Company.

  
 

  
(b)             Remedies.  The Director agrees that in the event of a breach or any threat of breach of this Section 8, the Company shall be entitled to an immediate injunction relief to prevent or stop such breach.  

  
 

  
(c)             Survival of Covenants.  The provisions of this Section 5 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements of this Section 8.

  
 

  
9.               Termination. With or without cause, the Company and Director may each terminate this Agreement at any time upon ten (10) days written notice, and the Company shall be obligated to pay to Director the compensation and expenses due up to the date of the termination. Nothing contained herein or omitted herefrom shall prevent the shareholder(s) of the Company from removing Director with immediate effect at any time for any reason. 

  
 

  
10.             Amendments and Waiver. No supplement, modification or amendment of this Agreement will be binding unless executed in writing by both parties. No waiver of any provision of this Agreement on a particular occasion will be deemed or will constitute a waiver of that provision on a subsequent occasion or a waiver of any other provision of this Agreement. 

  
 

  
11.             Binding Effect. This Agreement will be binding upon and inure to the benefit of and be enforceable by the parties and their respective successors and assigns. 

  
 

  
12.             Severability. The provisions of this Agreement are severable, and any provision of this Agreement that is held by a court of competent jurisdiction to be invalid, void, or otherwise unenforceable in any respect will not affect the validity or enforceability of any other provision of this Agreement. 

  
 

  
13.             Governing Law. This Agreement will be governed by and construed and enforced in accordance with the laws of the State of Delaware applicable to contracts made and to be performed in that state without giving effect to the principles of conflicts of laws. 

  
 

  
14.             Notice. Any and all notices referred to herein shall be sufficient if furnished in writing at the addresses specified on the signature page hereto or, if to the Company, to the Company’s address as specified in filings made by the Company with the U.S. Securities and Exchange Commission. 

  
 

  
15.             Assignment. The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder shall inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of Director under this Agreement are personal and therefore Director may not assign any right or duty under this Agreement without the prior written consent of the Company. 

  
 

  
 

  

  
 

  
16.             Entire Agreement. Except as provided elsewhere herein, this Agreement sets forth the entire agreement of the parties with respect to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect to such subject matter. 

  
 

  
17.             Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument. Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes. 

  
 

  
[Signature Page Follows]

  
 

  
 

  

  
 

  
IN WITNESS WHEREOF, the parties hereto have caused this Independent Director Agreement to be duly executed and signed as of the day and year first above written. 

  
 

  
  	
  
 

	
  
“NEURALSTEM, INC.”

	
  
 

	
  
 

	
  
 

	
  
By:

	
  
 

	
  
 

	
  
Name:

	
  
 

	
  
Title:

	
  
 

	
  
 

	
  
 

	
  
DIRECTOR

	
  
 

	
  
 

	
  
 

	
  
 

	
  
 

	
  
Name:

	
  
 

	
  
Address:SIXTH Amendment
to Credit Agreement

 

This SIXTH AMENDMENT
TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of March 6, 2014 by and among Bacterin
International, Inc., a Nevada corporation (the “Borrower”), BACTERIN INTERNATIONAL HOLDINGS,
INC., a Delaware corporation (“Holdings”), and ROS
Acquisition Offshore LP, a Cayman Islands Exempted Limited Partnership (the “Lender”).

 

WHEREAS, the Borrower
and the Lender are party to that certain Credit Agreement, dated as of August 24, 2012 (as amended by that certain First Amendment
to Credit Agreement, dated as of May 16, 2013, as further amended by that certain Waiver and Second Amendment to Credit Agreement,
dated as of August 12, 2013, as further amended by that certain Waiver and Third Amendment to Credit Agreement, dated as of August
12, 2013, as further amended by that certain Fourth Amendment to Credit Agreement, dated as of August 30, 2013, and as further
amended by that certain Waiver and Fifth Amendment to Credit Agreement, dated as of November 14, 2013, the “Credit Agreement”),
pursuant to which the Lender has extended credit to the Borrower on the terms set forth therein;

 

WHEREAS, the Borrower
has advised the Lender that it opened a new Deposit Account (as such term is defined in the Security Agreement) with Silicon Valley
Bank (Account #3301057621, the “Replacement SVB Account”) to replace an existing Deposit Account with Silicon
Valley Bank due to fraudulent activity in the existing Deposit Account but did not cause Silicon Valley Bank to amend its existing
Control Agreement (as such term is defined in the Security Agreement) to specifically include the Replacement SVB Account as required
by Section 4.1.2(a) of the Security Agreement, and therefore an Event of Default may have occurred under Section 9.1.4 of the Credit
Agreement (the “Possible Default”);

 

WHEREAS, the Borrower
has requested that the Lender waive the Possible Default and amend the Credit Agreement, as more fully described herein; and

 

WHEREAS, the Lender
is willing to waive the Possible Default and agree to such amendment, but only upon the terms and subject to the conditions set
forth herein.

 

NOW, THEREFORE,
in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

1.          Definitions;
Loan Document. Capitalized terms used herein without definition shall have the meanings assigned to such terms in the Credit
Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents.

 

2.          Amendments
to Section 1.1. Section 1.1 of the Credit Agreement is hereby amended by amending and restating the defined terms “Delayed
Draw Closing Date”, “Delayed Draw Commitment Amount” and “Delayed Draw Commitment Termination Date”
in their entireties to read as follows:

 

    	 

    	 

    

  

“Delayed Draw Closing Date”
means the date of the making of the Delayed Draw Loan hereunder, which in no event shall be later than March 7, 2014.

 

“Delayed Draw Commitment Amount”
means $4,000,000.

 

“Delayed Draw Commitment Termination
Date” means the earlier to occur of (i) the Delayed Draw Closing Date (immediately after the making of the Delayed Draw
Loan on such date) and (ii) March 8, 2014, if the Delayed Draw Loan shall not have been made hereunder prior to such date.

 

3.          Amendment
to Section 3.2(b). Section 3.2(b) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

(b) Commencing with the Fiscal Quarter ending
on September 30, 2016, the Borrower shall, on the last Business Day of each Fiscal Quarter, unless waived by the Lender at least
three Business Days prior to such date, make a scheduled principal payment of $1,666,667 (or such lesser amount as the Lender may
specify at least three Business Days prior to such date) of the Initial Loan and $333,333 (or such lesser amount as the Lender
may specify at least three Business Days prior to such date) of the Delayed Draw Loan, or, in each case if less, the remaining
outstanding principal amount of such Loan.

 

4.          Deletion
of Section 5.1.17. Each of Section 5.1.17 of the Credit Agreement and each reference thereto in the Credit Agreement is
hereby deleted in its entirety.

 

5.          Waiver.
The Lender hereby waives the Possible Default and agrees not to exercise any rights or remedies that may be available to it as
a result of the occurrence thereof.

 

6.          Restricted
Stock Grant. Holdings hereby agrees to grant and issue to the Lender, and the Lender hereby accepts, as consideration for
the Lender agreeing to execute this Amendment, and for no additional consideration, 1,500,000 shares of the common stock of Holdings
(the “Shares”), which shall be issued by Holdings to the Lender in certificated form as soon as reasonably practicable,
but in any event on or prior to March 28, 2014, subject to the last sentence of this Section 6. The Shares have not been registered
under the Securities Act of 1933, as amended (the “Securities Act”), and will not be able to be transferred by the
Lender, other than pursuant to an effective registration statement, or exemption from registration requirements under the Securities
Act and other applicable securities laws, and will contain a legend to that effect. Issuance of the Shares requires additional
listing approval by the NYSE MKT exchange, and Holdings shall use its reasonable best efforts to obtain such approval as soon as
reasonably practicable. If such approval is not received prior to March 28, 2014, then in lieu of issuing the Shares to the Lender,
the last two sentences of Section 3.2 of the Credit Agreement shall hereby automatically be amended and restated in their entirety
to read as follows:

 

At such time
as the Borrower pays, prepays or repays, or is required to pay, prepay or repay, any principal amount of the Loans, whether on
the Maturity Date or otherwise, whether voluntarily or involuntarily (if involuntarily, whether required by this Agreement, the
Royalty Agreement or any other Loan Document) and whether before or after acceleration of the Obligations, including without limitation
any payment pursuant to any provision of this Section 3.2, the Borrower shall pay to the Lender a fee in the amount equal
to 8.5% of the aggregate principal amount of such payment, prepayment or repayment. For the avoidance of doubt, any such fees paid
by the Borrower to the Lender shall not be included in clause (ii) of the definition of “Recovered Amount” for purposes
of the Royalty Agreement.

 

    	-2-

    	 

    

  

7.          Conditions
to Effectiveness of Amendment. This Amendment, including the Lender’s consent to the Waiver in Section 5, shall become
effective upon receipt by the Lender of (i) a Loan Request for the Delayed Draw Loan, duly executed and delivered by the Borrower
pursuant to Section 2.3 of the Credit Agreement, (ii) a Closing Date Certificate, duly executed and delivered by the Borrower,
(iii) a solvency certificate, in form and substance satisfactory to the Lender, duly executed and delivered by each of the Borrower
and Holdings, and (iv) counterpart signatures to this Amendment, duly executed and delivered by each of the Borrower and Holdings.

 

8.          Condition
to Effectiveness of Waiver. To induce the Lender to agree to the terms of Section 5, the Borrower agrees that it shall
cause a Control Agreement to be executed for the Replacement SVB Account by March 14, 2014, such Control Agreement to be in form
and substance satisfactory to the Lender (the “Condition”). The failure by the Borrower to satisfy the Condition
shall be an immediate Event of Default.

 

9.          Expenses.
The Borrower agrees to pay on demand all expenses of the Lender (including, without limitation, the fees and out-of-pocket expenses
of Covington & Burling LLP, counsel to the Lender, and of local counsel, if any, who may be retained by or on behalf of the
Lender) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and the transactions
contemplated hereby.

 

10.         Representations
and Warranties. The Borrower and Holdings each represents and warrants to the Lender as follows:

 

(a)          After
giving effect to this Amendment, the representations and warranties of the Borrower and the Guarantors contained in the Credit
Agreement or any other Loan Document shall, (i) with respect to representations and warranties that contain a materiality qualification,
be true and correct in all respects on and as of the date hereof, and (ii) with respect to representations and warranties that
do not contain a materiality qualification, be true and correct in all material respects on and as of the date hereof, and except
that the representations and warranties limited by their terms to a specific date shall be true and correct as of such date.

 

(b)          After
giving effect to this Amendment, no Default or Event of Default under the Credit Agreement will occur or be continuing.

 

(c)          The
authorized capital stock of Holdings, as of immediately prior to the date hereof, consists of (i) 95,000,000 shares of common stock,
par value $0.000001 per share, 53,358,458 of which are issued and outstanding as of February 27, 2014, and (ii) 5,000,000 shares
of preferred stock, par value $0.000001 per share, none of which are issued and outstanding as of the date of this Amendment.

 

    	-3-

    	 

    

 

(d)          Other
than (i) up to 9,000,000 shares of common stock reserved for issuance pursuant to the Equity Incentive Plan of Holdings, (ii) an
option to purchase 2,000,000 shares of common stock granted outside of the Equity Incentive Plan, and (iii) warrants to purchase
11,660,603 shares of common stock, except as granted pursuant to this Amendment, as of the date of this Amendment, there are no
outstanding options, warrants, phantom equity, rights (including conversion or preemptive rights and rights of first refusal),
proxy or stockholder agreements, or agreements of any kind for the purchase or acquisition from Holdings of any of its securities.

 

(e)          All
issued and outstanding shares of Holdings’ common stock and preferred stock (i) have been duly authorized and validly issued
and are fully paid and nonassessable, and (ii) were issued in compliance with all applicable state and federal laws concerning
the issuance of securities.

 

(f)          The
rights, preferences, privileges and restrictions of the Shares are as stated in the Certificate of Incorporation of Holdings (the
“Charter”). When issued in compliance with the provisions of this Amendment, the Charter and applicable law,
the Shares will be validly issued, fully paid and nonassessable, and will be free of any liens or encumbrances other than liens
and encumbrances created by or imposed upon the Lender; provided, however, that the Shares may be subject to restrictions on transfer
under state and/or federal securities laws or as otherwise required by such laws at the time a transfer is proposed. The issuance
of the Shares is not and will not be subject to any preemptive rights or rights of first refusal that have not been properly waived
or complied with. Holdings has no obligation (contingent or otherwise) to purchase or redeem any of its capital stock. Except for
(i) the warrants issued in connection with Holdings’ issuance of common stock on June 10, 2013, and (ii) the warrants issued
in connection with bridge financings in 2009 and 2010, the issuance of the Shares pursuant to this Amendment will not result in
any change to the exercise price, conversion price, conversion rate, or number of shares of Holdings’ capital stock issuable
upon the exercise or conversion of any of Holdings’ capital stock, options, warrants or other rights to acquire the Holdings’
capital stock.

 

11.         No
Implied Amendment or Waiver. Except as expressly set forth in this Amendment, this Amendment shall not, by implication
or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Lender under the Credit Agreement
or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained
in the Credit Agreement or the other Loan Documents, all of which shall continue in full force and effect. Nothing in this Amendment
shall be construed to imply any willingness on the part of the Lender to agree to or grant any similar or future amendment, consent
or waiver of any of the terms and conditions of the Credit Agreement or the other Loan Documents.

 

12.         Waiver
and Release. TO INDUCE THE LENDER TO AGREE TO THE TERMS OF THIS AMENDMENT, THE BORROWER AND HOLDINGS EACH REPRESENTS AND
WARRANTS THAT AS OF THE DATE HEREOF THERE ARE NO CLAIMS OR OFFSETS AGAINST OR RIGHTS OF RECOUPMENT WITH RESPECT TO OR DEFENSES
OR COUNTERCLAIMS TO ITS OBLIGATIONS UNDER THE LOAN DOCUMENTS AND IN ACCORDANCE THEREWITH IT:

 

    	-4-

    	 

    

  

(a)          WAIVES
ANY AND ALL SUCH CLAIMS, OFFSETS, RIGHTS OF RECOUPMENT, DEFENSES OR COUNTERCLAIMS, WHETHER KNOWN OR UNKNOWN, ARISING PRIOR TO THE
DATE HEREOF; AND

 

(b)          RELEASES
AND DISCHARGES THE LENDER, ITS AFFILIATES AND ITS AND THEIR OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, SHAREHOLDERS AND ATTORNEYS
(COLLECTIVELY THE “RELEASED PARTIES”) FROM ANY AND ALL OBLIGATIONS, INDEBTEDNESS, LIABILITIES, CLAIMS, RIGHTS,
CAUSES OF ACTION OR DEMANDS WHATSOEVER, WHETHER KNOWN OR UNKNOWN, SUSPECTED OR UNSUSPECTED, IN LAW OR EQUITY, WHICH THE BORROWER
EVER HAD, NOW HAS, CLAIMS TO HAVE OR MAY HAVE AGAINST ANY RELEASED PARTY ARISING PRIOR TO THE DATE HEREOF AND FROM OR IN CONNECTION
WITH THE LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED THEREBY.

 

13.         Counterparts;
Governing Law. This Amendment may be executed in any number of counterparts and by different parties hereto on separate
counterparts, each of such when so executed and delivered shall be an original, but all of such counterparts shall together constitute
but one and the same agreement. Delivery of an executed counterpart of a signature page of this Amendment by fax transmission or
other electronic mail transmission (e.g., “pdf” or “tif”) shall be effective as delivery of a manually
executed counterpart of this Amendment. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS
OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF
NEW YORK).

 

[Remainder
of Page Intentionally Left Blank]

 

    	-5-

    	 

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year
first above written.

 

	 	
        BACTERIN INTERNATIONAL, INC.,

        as the Borrower

	 	 
	 	By:	/s/ John P. Gandolfo
	 	Name:	John P. Gandolfo
	 	Title:	Chief Financial Officer
	 	 	 
	 	BACTERIN INTERNATIONAL HOLDINGS, INC., as Holdings and a Guarantor
	 	 	 
	 	By:	/s/ John P. Gandolfo
	 	Name:	John P. Gandolfo
	 	Title:	Chief Financial Officer
	 	 	 
	 	ROS Acquisition Offshore LP,

as the Lender
	 	By ROS Acquisition Offshore GP Ltd.,
	 	its General Partner
	 	By OrbiMed Advisors LLC,
	 	its investment manager
	 	 	 
	 	By:	/s/ Samuel D. Isaly
	 	Name:	Samuel D. Isaly
	 	Title:	Managing Member

 

Signature Page to Sixth Amendment to
Credit Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]